Featured Research

from universities, journals, and other organizations

Promising Early Evidence Of The Superior Benefits Of Drug Therapy For Diabetic Eye Disease

Date:
April 30, 2008
Source:
Juvenile Diabetes Research Foundation International
Summary:
A drug for the treatment of diabetic eye disease has performed better in clinical trials than the current standard treatment using laser surgery. "These are very encouraging results, showing that drugs we have been testing in human clinical trials can be effective in slowing or stopping the effects of eye disease brought on by diabetes," said one of the scientists.

A JDRF collaboration between Johns Hopkins researchers and Genentech has shown that a drug for the treatment of diabetic eye disease has performed better in clinical trials than the current standard treatment using laser surgery.

According to Barbara Araneo, Ph.D., director of the complications program at JDRF, "These are very encouraging results, showing that drugs we have been testing in human clinical trials can be effective in slowing or stopping the effects of eye disease brought on by diabetes."

These findings, representing the six-month end-point evaluation of the READ-2 clinical trial coordinated by The Johns Hopkins University, were presented Monday at the 2008 Annual Meeting of The Association for Research in Vision and Ophthalmology, in Fort Lauderdale, Florida.

The multi-center READ-2 Study (Ranibizumab for Edema of the mAcula in Diabetes), which began in December 2006, was designed to test the long-term safety and effectiveness of injections of the drug ranibizumab in patients with diabetic macular edema, a condition characterized by swelling of the central portion of the retina, or macula, at the back of the eye. In addition, the trial sought to determine the comparative efficacy of ranibizumab versus conventional treatment -- laser photocoagulation therapy -- or both together.

Macular edema, one of the most common causes of blindness, occurs when fluid and protein deposits collect on or under the macula, causing it to thicken and swell.

Participating in the clinical trial were 126 diabetic patients (average age 62) with documented Diabetic Macular Edema prior to enrollment; the majority had 20/80 vision in the eye that was treated. Patients were randomly assigned to receive one of three interventions: ranibizumab, laser photocoagulation, or a combination of the two treatments. At each visit over the course of the six-month treatment period, patients were evaluated for vision, retinal thickening, and general eye health. Although the study ended at six months, patients will be monitored for two years.

Patients treated with ranibizumab experienced significantly greater improvements in visual acuity, or clarity of vision, compared with patients receiving either of the other interventions. On average, the vision of ranibizumab-treated patients improved to 20/63 at month six, compared with essentially unchanged acuity scores of about 20/80 in both the laser and the combination treatment groups.

In addition, patients treated with ranibizumab had a 56 percent reduction in excess retinal thickness, whereas only an 11 percent reduction was seen in those receiving laser treatments.

The READ-2 study, which was funded as part of JDRF's research addressing the complications of type 1 diabetes, is also supported by Johns Hopkins and the pharmaceutical company Genentech. It builds on the results of the 2007 READ-1 Study, a Phase 1 trial that was also a collaboration with these two organizations. This first trial established the ability of ranibizumab to reduce edema and improve visual acuity in patients with diabetic macular edema. The READ-2 study is taking place at 14 clinical centers around the United States, including at the University of California, San Francisco, the Yale Eye Center in New Haven, Connecticut, and Emory University in Atlanta, Georgia. The study is no longer recruiting patients.

About Ranibizumab

Ranibizumab is designed to block a natural protein in the body called vascular endothelial growth factor (VEGF), which is produced in excessive amounts in people with diabetes. VEGF causes leakage in the small blood vessels of the eye that can lead to vision loss and blindness. In the Phase 1 clinical trial, Dr. Quan Dong Nguyen, Dr. Peter Campochiaro, and colleagues at the Wilmer Eye Institute of Johns Hopkins University treated 10 patients with chronic diabetic macular edema with ranibizumab. The trial participants received injections of the drug, with follow-up injections at one, two, four, and six months. The outcome revealed that ranibizumab significantly reduced macular swelling in all patients and improved visual acuity. The Phase 1 clinical trial for DME followed the investigative work by Genentech, Inc., who manufactures ranibizumab. Ranibizumab was approved by the U.S. Food and Drug Administration for the treatment of patients with wet age related macular degeneration in June 2006.


Story Source:

The above story is based on materials provided by Juvenile Diabetes Research Foundation International. Note: Materials may be edited for content and length.


Cite This Page:

Juvenile Diabetes Research Foundation International. "Promising Early Evidence Of The Superior Benefits Of Drug Therapy For Diabetic Eye Disease." ScienceDaily. ScienceDaily, 30 April 2008. <www.sciencedaily.com/releases/2008/04/080429130924.htm>.
Juvenile Diabetes Research Foundation International. (2008, April 30). Promising Early Evidence Of The Superior Benefits Of Drug Therapy For Diabetic Eye Disease. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2008/04/080429130924.htm
Juvenile Diabetes Research Foundation International. "Promising Early Evidence Of The Superior Benefits Of Drug Therapy For Diabetic Eye Disease." ScienceDaily. www.sciencedaily.com/releases/2008/04/080429130924.htm (accessed October 22, 2014).

Share This



More Mind & Brain News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
Portable Breathalyzer Gets You Home Safely

Portable Breathalyzer Gets You Home Safely

Buzz60 (Oct. 21, 2014) Breeze, a portable breathalyzer, gets you home safely by instantly showing your blood alcohol content, and with one tap, lets you call an Uber, a cab or a friend from your contact list to pick you up. Sean Dowling (@SeanDowlingTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Your Birth Season Might Determine Your Temperament

Your Birth Season Might Determine Your Temperament

Newsy (Oct. 20, 2014) A new study says the season you're born in can determine your temperament — and one season has a surprising outcome. Video provided by Newsy
Powered by NewsLook.com
Movies Might Desensitize Violence For Parents, Not Just Kids

Movies Might Desensitize Violence For Parents, Not Just Kids

Newsy (Oct. 20, 2014) A study suggests that parents become desensitized to violent movies as well as children, which leads them to allow their kids to view violent films. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins